Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Mar
17
2020
Clean Hands Can Stop More than COVID-19: Antitrust Risks in Times of Supply and Demand Shocks McDermott Will & Emery
Mar
18
2020
CMS Rolls Out Part D Insulin Payment Model: Aims to Lower Out-of-Pocket Expenses McDermott Will & Emery
Mar
23
2020
TTB and FDA Relax Restrictions on the Production of Hand Sanitizers by Alcohol Manufacturers McDermott Will & Emery
Sep
14
2023
Key Takeaways | Hospital and Health System Digital Health Spotlight: It’s all About the Patient! McDermott Will & Emery
Sep
19
2023
Top Takeaways | Specialty Spotlight: Gastroenterology McDermott Will & Emery
Jul
2
2016
Second Circuit Affirms Dismissal of Sham Citizen Petition Claim, Summary Judgment on False Advertising Claims McDermott Will & Emery
Sep
29
2016
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategy (REMS) Determinations McDermott Will & Emery
Jun
10
2020
Fee Shifting Under § 285 Does Not Apply to Conduct Solely Arising in IPR McDermott Will & Emery
Dec
8
2023
McDermottPlus Check-Up: December 8, 2023 McDermott Will & Emery
Mar
1
2024
FDA Finalizes Revised Medical Device Quality System Requirements, Issues Remote Regulatory Assessments Guidance McDermott Will & Emery
Aug
24
2020
HSS Rescinds FDA's "Informal" Ability to Require Premarket Review pf LDTS Without Formal Rulemaking McDermott Will & Emery
Oct
15
2020
Leaders Moving 2020 Forward - Kimberly Manna, CEO of Panama Jack [VIDEO] McDermott Will & Emery
Apr
9
2024
This Week in 340B: April 2 – April 8, 2024 McDermott Will & Emery
Jun
12
2017
FDA Extends Unique Device Identification (UDI) System Compliance Deadlines for Certain Low-Risk Medical Devices McDermott Will & Emery
Jun
20
2017
Supreme Court Analyzes Key Provisions of Biologics Price Competition and Innovation Act of 2009 McDermott Will & Emery
Mar
10
2021
CDC Releases Initial Guidance: Fully Vaccinated People Can Visit Others, May Not Have to Quarantine After COVID-19 Exposure McDermott Will & Emery
Mar
31
2021
340B in 2021: What Covered Entities and Their Partners Need to Know Now Recap McDermott Will & Emery
Dec
19
2011
Treasury Clarifies 5 Percent Safe Harbor Ownership Guidelines for Section 1603 Grants for Renewable Energy Projects McDermott Will & Emery
Jan
4
2013
Key Energy Tax Provisions Included in ‘Fiscal Cliff’ Legislation McDermott Will & Emery
Mar
9
2013
International Trade Actions Complicate Global Market For Renewable Energy Businesses, Particularly Solar Sector McDermott Will & Emery
Jun
1
2013
Patent Exhaustion Rejected: Patented Seed Purchaser Has No Right to Make Copies McDermott Will & Emery
Jun
30
2013
Generic Versions of AstraZeneca’s Pulmicort Respules Enjoined from Launch Pending Appeal in Patent Infringement Case McDermott Will & Emery
Aug
8
2013
Acquiring Italian Distressed Renewable Energy Assets McDermott Will & Emery
Sep
6
2013
Department of Energy (DOE) Announces Funding for Hydrokinetic Power Projects McDermott Will & Emery
Oct
29
2021
FDA Issues Good Machine Learning Practice Guiding Principles McDermott Will & Emery
Jan
24
2014
Massachusetts DOER (Department of Energy Resources) Proposes to Expand to 1600 MW Generation Eligible to Create SRECs (Solar Carve-Out II Program) McDermott Will & Emery
Jan
21
2022
Legal Considerations for Ready-to-Drink Cocktails McDermott Will & Emery
Mar
26
2014
D.C. Circuit Denies Rehearing on Nuclear Waste Fee Decision McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins